|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910817223903321 |
|
|
Autore |
Patlak Margie |
|
|
Titolo |
Developing biomarker-based tools for cancer screening, diagnosis, and treatment : the state of the science, evaluation, implementation, and economics / / Margie Patlak and Sharyl Nass, rapporteurs ; National Cancer Policy Forum |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Washington, DC, : National Academies Press, c2006 |
|
|
|
|
|
|
|
ISBN |
|
0-309-18061-9 |
1-280-70492-6 |
9786610704927 |
0-309-65814-4 |
|
|
|
|
|
|
|
|
Edizione |
[1st ed.] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (112 p.) |
|
|
|
|
|
|
Altri autori (Persone) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Tumor markers |
Biochemical markers |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Bibliographic Level Mode of Issuance: Monograph |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references. |
|
|
|
|
|
|
Nota di contenuto |
|
Frontmatter -- Reviewers -- Contents -- Introduction -- Overview of Technologies Used to Discover Cancer Biomarkers -- Meeting the Technical Challenges of Biomarker Validation and Qualification -- Coordinating the Development of Biomarkers and Targeted Therapies -- Biomarker Development and Regulatory Oversight -- Assessment and Adoption of Biomarker-Based Technologies -- Economic Impact of Biomarkers -- Clinical Development Strategies for Biomarker Utilization Discussion -- Strategies for Implementing Standardized Biorepositories Discussion -- Strategies for Determining Analytic Validity and Clinical Utility of Biomarkers Discussion -- Strategies to Develop Biomarkers for Early Detection Discussion -- Mechanisms for Developing an Evidence Base Discussion -- Evaluation of Evidence in Decision Making Discussion -- Incorporating Biomarker Evidence Into Clinical Practice Discussion -- Acronyms -- Glossary -- References -- Appendixes -- Appendix A Workshop Agenda -- Appendix B Workshop Speakers, Moderators, Invited Discussants, and Participants. |
|
|
|
|
|
|
|